Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Zonghai Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2448-3636; OpenAlex author ID A5036977660. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 5

  1. CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. Co-author DOI 10.1002/adhm.202500546↗
  2. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. Last author DOI 10.1111/bph.16505↗
  3. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Last author DOI 10.1016/j.ymthe.2023.09.010↗
  4. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. Last author DOI 10.1186/s12967-023-04080-z↗
  5. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. Last author DOI 10.1007/s13238-017-0472-9↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hua Jiang · 2 shared papers, 2023–2025 · strength 0.44
  2. Ruixin Sun · 2 shared papers, 2023 · strength 0.35
  3. Yifan Liu · 2 shared papers, 2023 · strength 0.35
  4. Yaru Zhao · 1 shared paper, 2025 · strength 0.27
  5. Yue Qing · 1 shared paper, 2025 · strength 0.27
  6. Christopher Heeschen · 1 shared paper, 2025 · strength 0.27
  7. Hua Jiang · 2 shared papers, 2017–2023 · strength 0.25
  8. Sun Ruixin · 1 shared paper, 2024 · strength 0.22
  9. Yiwei Dong · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.